Much more than a ‘party drug’

Psilocybin, MDMA or LSD might associate with party drugs but their therapeutic value is being discovered worldwide. Ian Roullier took part in two clinical trials that looked at the effects of psilocybin on depression. Through his personal experience, Roullier shares his insights on psychedelic-assisted therapy, its potential value to patients and what is needed to boost research in this field. 

What is The Health Brief?

Welcome to EURACTIV's health Brief, your weekly update on health policy in the EU from EURACTIV's health news team: Gerardo Fortuna, Giedre Peseckyte and Clara Bauer.